More than six years after he finished serving eight months of a two-year prison sentence, Dr. Darryl Jordan Gebien wants to talk about his experience, in hopes of helping other people with addictions.
At the heart of Novo Nordisk’s acquisition of Montreal-based Inversago Pharma is an oral agonist designed to block the receptor protein CB1, which plays an important role in metabolism and appetite regulation.
The deal would allow the company to emerge from bankruptcy as a different entity, with its profits used to fight the opioid epidemic. Members of the Sackler family would contribute up to $6 billion.
